Indian Pharma exports to US may increase in 2017-18, Care Ratings
The Dollar Business Bureau Indian Pharma exports to the US may increase in 2017-18 despite pricing pressure and stiff competition. A report released by Care Ratings said that $50 billion worth of drugs are expected to become 'off-patent' in the current year giving hope to the Indian Pharma export market. "The pharma export volumes from India to US, however, are expected to rise. This will be backed by about $55 billion expected sales gain to generics drugs on account of branded drugs going off patent during 2017-19 which will create an opportunity for CRAMS segment. We expect growth rate for CRAMS (Contract Research and Manufacturing Services) to be higher compared to average growth rate of the industry. These factors are likely to support pharma exports from India," ...
Indian pharma major to acquire two US firms, deal worth $550 mn
The Dollar Business Bureau Cipla EU, the UK arm of the Mumba-based Cipla Ltd., has entered into definitive agreements to acquire two US-based firms— InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc. The deal which is subject to certain closing conditions is valued at $550 million. This acquisition, which is being seen as the second landmark acquisition in Cipla’s history, will give the company scale in the US generics market through a wide range of product portfolio in CNS, CVS, anti-infectives, diabetes as well as other value added generic drugs, , the company said in a statement on Friday. While acquisition of InvaGen, a skilled R&D organization, offers a large capacity manufacturing base in Hauppauge, New York, Exelan provides Cipla with an access ...
